HKEX Filings
-
Apr 20, 2022
VOLUNTARY ANNOUNCEMENT - CLOVER'S EFFICACY DATA IN PREVIOUSLY-INFECTED INDIVIDUALS IS PUBLISHED IN LANCET INFECTIOUS DISEASE
-
Apr 19, 2022VOLUNTARY ANNOUNCEMENT - CLOVER PRESENTS UPDATED DURABILITY AND BOOSTER DATA FOR COVID-19 VACCINE CANDIDATE AT WORLD VACCINE CONGRESS WASHINGTON 2022
-
Apr 19, 20222021 Annual Report
-
Apr 6, 2022Monthly Return of Equity Issuer on Movements in Securities for the Month ended March 31, 2022
-
Mar 31, 2022GRANT OF OPTIONS PURSUANT TO THE POST-IPO SHARE OPTION PLAN AND GRANT OF RSUS PURSUANT TO THE RSU SCHEME
-
Mar 29, 2022PROPOSED ADOPTION OF THE AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION
-
Mar 29, 2022ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2021
-
Mar 18, 2022CLARIFICATION ANNOUNCEMENT
-
Mar 17, 2022VOLUNTARY ANNOUNCEMENT - CLOVER'S COVID-19 VACCINE CANDIDATE DEMONSTRATED DURABLE HIGH PROTECTION AND STRONG IMMUNE RESPONSE AGAINST OMICRON AS A BOOSTER
-
Mar 17, 2022DATE OF BOARD MEETING
-
Mar 11, 2022CHANGE OF ADDRESS OF HEADQUARTERS IN THE PRC
-
Mar 4, 2022Monthly Return of Equity Issuer on Movements in Securities for the Month ended February 28, 2022
-
Feb 24, 2022VOLUNTARY ANNOUNCEMENT - INCLUSION ON THE HANG SENG COMPOSITE INDEX
-
Feb 14, 2022VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE
-
Feb 7, 2022Monthly Return of Equity Issuer on Movements in Securities for the Month ended January 31, 2022
-
Jan 28, 2022WAIVER FROM STRICT COMPLIANCE WITH RULE 10.07(1)(B) OF THE LISTING RULES
-
Jan 21, 2022VOLUNTARY ANNOUNCEMENT - PUBLICATION IN THE LANCET SHOWING THAT SCB-2019 (CPG 1018/ALUM) IN A PHASE 2/3 CLINICAL TRIAL DEMONSTRATES EFFICACY AGAINST ENTIRE SEVERITY SPECTRUM OF COVID-19
-
Jan 6, 2022Monthly Return of Equity Issuer on Movements in Securities for the Month ended December 31, 2021
-
Jan 5, 2022VOLUNTARY ANNOUNCEMENT - DOSING OF FIRST PARTICIPANTS WITH HOMOLOGOUS BOOSTER DOSE OF COVID-19 VACCINE CANDIDATE IN SPECTRA
-
Dec 22, 2021CHANGE OF JOINT COMPANY SECRETARY, AUTHORIZED REPRESENTATIVE AND PROCESS AGENT AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES
